Table 3. Ongoing PD-1/PD-L1 inhibitors trials in TNBC.

Trial ID	Status	Phase	Cancer type	Intervention
PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TNBC, triple-negative breast cancer; AR, androgen receptor; AJCC, American Joint Committee on Cancer.
PD-1 inhibitor
NCT03504488	Recruiting	Phase 1/2	Non-small cell lung cancer; TNBC; melanoma; head and neck cancer	CAB-ROR2-ADC/CAB-ROR2-ADC + a PD-1 inhibitor
NCT03945604	Unknown	Phase 1	Recurrent and metastatic TNBC	SHR-1210 + apatinib + fluzoparib
NCT04577963	Recruiting	Phase 1b/2	Advanced, refractory TNBC	Fruquintinib + tislelizumab
NCT03362060	Active, not recruiting	Phase 1b	Advanced, refractory TNBC	PVX-410 and pembrolizumab
NCT04639245	Recruiting	Phase 1/2	Anatomic stage IV breast cancer (AJCC 8th); metastatic lung non-small cell carcinoma; metastatic malignant solid neoplasm; metastatic TNBC; metastatic urothelial carcinoma; prognostic stage IV breast cancer (AJCC 8th); stage IV/IVA/IVB lung cancer (AJCC 8th)	Cyclophosphamide + MAGE-A1-specific T cell receptor-transduced autologous T-cells atezolizumab
NCT03667716	Recruiting	Phase 1	Advanced cancer; ovarian cancer; lung cancer; endometrial cancer; ovarian neoplasm; TNBC; malignant colorectal cancer	COM701/COM701 with opdivo (nivolumab)
NCT05076682	Recruiting	Phase 2	Metastatic TNBC	Choline/sodium cromoglicate with anti-PD-1 immunotherapy
NCT03394287	Completed	Phase 2	Advanced TNBC	SHR-1210 + apatinib
PD-L1 inhibitor
NCT04837209	Recruiting	Phase 2	Metastatic, PD-L1 negative or immunotherapy-refractory TNBC	Niraparib + dostarlimab + radiation
NCT04739670	Not yet recruiting	Phase 2	Metastatic TNBC	Atezolizumab + bevacizumab + gemcitabine + carboplatin
NCT04360941	Recruiting	Phase 1	Metastatic AR+ TNBC	Palbociclib + avelumab